Meanwhile, de novo lipogenesis and cholesterogenesis lead to hepatic lipid accumulation and hyperlipidemia, primarily through the activation of lipogenic transcription factors called liver X receptor (LXR) and sterol regulatory element-binding protein-1c (SREBP-1c), and cholesterogenic regulators SREBP-2 and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), respectively [4,6]. Here, SREBF2 is linked to hyperlipidemia.